Novartis reported Phase 3 data showing its experimental antimalarial GanLum (ganaplacide + lumefantrine) met the primary endpoint of noninferiority versus standard care across 1,688 patients in sub‑Saharan Africa. The combination achieved cure rates that exceed World Health Organization thresholds and demonstrated activity against drug‑resistant parasites and potential to block transmission. Novartis developed ganaplacide with the Medicines for Malaria Venture; the program targets parasite protein transport mechanisms different from artemisinin derivatives, aiming to broaden efficacy where resistance is rising. The company said it will seek regulatory approvals promptly based on the Phase 3 package and highlighted the public‑health implications of a novel oral therapy after decades without new drug classes. Clarification: noninferiority means the new regimen performed at least as well as the current standard; regulatory filings will follow regional and global review processes.